Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
06/23/2022 - 07:00 AM
NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details:
Webcast Registration link: https://edge.media-server.com/mmc/p/y3zwhkuk
For further information, please contact: Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600 Alex Price / Nicholas Moore Investec Bank plc (Joint Broker) Tel: 020 7597 4000 Gary Clarence / Daniel Adams Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 CapComm Partners Tel: 415-389-6400 or investors@renalytix.com Peter DeNardo
About Renalytix www.kidneyintelx.com ). For more information, visit www.renalytix.com .
RNLX Rankings
#4481 Ranked by Stock Gains
RNLX Stock Data
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Tags
Technology Services, Packaged Software, Health Care and Social Assistance, Diagnostic Imaging Centers
Country
United Kingdom
City
Penarth
About RNLX
renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev
